Skip to main content
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc. — Investor Relations & Filings

Ticker · ALLO ISIN · US0197701065 US Manufacturing
Open in API
Filings indexed 523 across all filing types
Latest filing 2022-04-26 Proxy Solicitation & In…
Country US United States of America
Listing US ALLO

About Allogene Therapeutics, Inc.

https://allogene.com/

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies. The company engineers T cells from healthy donors to create "off-the-shelf" treatments for cancer and autoimmune diseases. This approach is designed to enable on-demand availability, scalability, and reliability, contrasting with autologous therapies that use a patient's own cells. Allogene's pipeline utilizes multiplex gene-engineering and gene-editing capabilities. Its key investigational programs include cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma, ALLO-316 for clear cell renal cell carcinoma, and ALLO-329 for autoimmune disease.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is identified as a Schedule 14A Proxy Statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is labeled as 'Definitive Additional Materials' related to a proxy statement. Proxy statements are materials sent to shareholders to provide information and request votes for meetings. The document is short (1134 characters) and does not contain financial data or detailed reports but is clearly related to proxy solicitation. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI).
2022-04-26 English
DEF 14A
Proxy Solicitation & Information Statement
2022-04-26 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Proxy Statement filed pursuant to Schedule 14A under the Securities Exchange Act of 1934. It is related to the 2022 Annual Meeting of Stockholders of Allogene Therapeutics, Inc. The text includes detailed information about the meeting agenda, voting procedures, proposals to be voted on, and other proxy materials. It is not an Annual Report, Earnings Release, or any other financial report but rather a solicitation of shareholder votes and information about the meeting. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document length is substantial (15,000 characters), indicating it is the full proxy statement, not just a brief announcement or notice. Therefore, the correct classification is PSI with high confidence.
2022-04-14 English
SC TO-C Filing
Regulatory Filings
2022-04-14 English
PRIMARY DOCUMENT
Director's Dealing
2022-04-04 English
PRIMARY DOCUMENT
Director's Dealing
2022-04-01 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.